Nkarta News

Nkarta Analyst Ratings

BenzingaApr 10 07:31 ET

Analysts Offer Insights on Healthcare Companies: Evolus (EOLS) and Nkarta (NKTX)

TipRanksApr 10 07:00 ET

TD Cowen Reaffirms Their Buy Rating on Nkarta (NKTX)

TipRanksMar 26 07:25 ET

Stifel Nicolaus Keeps Their Buy Rating on Nkarta (NKTX)

TipRanksMar 25 22:05 ET

Nkarta Analyst Ratings

BenzingaMar 25 12:33 ET

HC Wainwright & Co. Maintains Buy on Nkarta, Raises Price Target to $22

BenzingaMar 25 12:33 ET

Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY)

TipRanksMar 22 07:10 ET

Nkarta's Strategic Pivot to NKX019 Spurs Buy Rating Amid Strong Financials and Promising Trial Prospects

TipRanksMar 22 06:45 ET

Buy Rating for Nkarta: Promising Future for NKX019 in Autoimmune Disease Treatment

TipRanksMar 22 06:26 ET

Nkarta's Strategic Focus and Financial Strength Underpin Buy Rating

TipRanksMar 22 06:27 ET

Nkarta Analyst Ratings

BenzingaMar 22 05:47 ET

Innovative NK-Cell Therapy: A Buy Rating for Nkarta's Groundbreaking Approach to Autoimmune Diseases

TipRanksMar 19 01:38 ET

Nkarta Analyst Ratings

BenzingaMar 5 08:57 ET

Leerink Partners Keeps Their Buy Rating on Nkarta (NKTX)

TipRanksFeb 18 23:47 ET

Nkarta Analyst Ratings

BenzingaJan 16 16:00 ET

Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Incyte (INCY) and Nkarta (NKTX)

TipRanksJan 11 01:31 ET

Stifel Nicolaus Sticks to Its Buy Rating for Nkarta (NKTX)

TipRanksJan 9 07:36 ET

Buy Rating for Nkarta's Stock Backed by Promising CAR-NK Therapy Developments and Strategic Advantages

TipRanksJan 9 05:55 ET

Buy Rating Reiterated for Nkarta Amid Promising Redosing Results and Broad Therapeutic Potential

TipRanksJan 8 15:35 ET

Buy Rating on Nkarta's Stock Amid Encouraging Clinical Trial Results for NKX101

TipRanksDec 13, 2023 02:16 ET